formica (![[info]](http://klab.lv/img/userinfo.gif){kind=small} formica) rakstīja, |
par vakcīnas efektivitāti
https://assets.publishing.service.gov.u
4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
Breast-feeding
It is unknown whether the COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk.
As with any vaccine, vaccination with COVID-19 mRNA Vaccine BNT162b2 may not protect all vaccine recipients.
No data are available on the use of COVID-19 mRNA Vaccine BNT162b2 in persons that have previously received a full or partial vaccine series with another COVID-19 vaccine.
The most frequent adverse reactions in participants 16 years of age and older were pain at the injection site (> 80%), fatigue (> 60%), headache (> 50%), myalgia (> 30%), chills (> 30%), arthralgia (> 20%) and pyrexia (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination
†
Throughout the safety follow-up period to date, acute peripheral facial paralysis (or palsy) was reported by four participants in the COVID-19 mRNA Vaccine group. .. No cases of acute peripheral facial paralysis (or palsy) were reported in the placebo group.
https://assets.publishing.service.gov.u
4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
Breast-feeding
It is unknown whether the COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk.
As with any vaccine, vaccination with COVID-19 mRNA Vaccine BNT162b2 may not protect all vaccine recipients.
No data are available on the use of COVID-19 mRNA Vaccine BNT162b2 in persons that have previously received a full or partial vaccine series with another COVID-19 vaccine.
The most frequent adverse reactions in participants 16 years of age and older were pain at the injection site (> 80%), fatigue (> 60%), headache (> 50%), myalgia (> 30%), chills (> 30%), arthralgia (> 20%) and pyrexia (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination
†
Throughout the safety follow-up period to date, acute peripheral facial paralysis (or palsy) was reported by four participants in the COVID-19 mRNA Vaccine group. .. No cases of acute peripheral facial paralysis (or palsy) were reported in the placebo group.
Nopūsties:
